Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.

Autores de IIS La Fe

• Esteban Ribera Pascuet

  Autor

• Juan Ginés Córdoba Cortijo

  Autor

• José López Aldeguer

  Autor

• María Jose Galindo Puerto

  Autor

• 

  Antonio Pineda Lucena

  Autor

Participantes ajenos a IIS La Fe

• Betancor G
• Garriga C
• Puertas MC
• Nevot M
• Anta L
• Blanco JL
• Pérez-Elías MJ
• de Mendoza C
• Martínez MA
• Martinez-Picado J
• Menéndez-Arias L
• Resistance Platform of the Spanish AIDS Research Network (ResRIS)
• Iribarren JA
• Caballero E
• Llibre JM
• Clotet B
• Jaén A
• Dalmau D
• Gatel JM
• Peraire J
• Vidal F
• Vidal C
• Riera M
• Gutiérrez F
• Álvarez M
• García F
• Pérez-Romero P
• Viciana P
• Leal M
• Palomares JC
• Viciana I
• Santos J
• Rodríguez P
• Gómez Sirvent JL
• Gutiérrez C
• Moreno S
• Pérez-Olmeda M
• Alcamí J
• Rodríguez C
• del Romero J
• Cañizares A
• Pedreira J
• Miralles C
• Ocampo A
• Morano L
• Aguilera A
• Garrido C
• Manuzza G
• Poveda E
• Soriano V

Grupos

• Infección Grave

  

  Investigador Principal

  María Ángeles Tormo Mas

• Infecciones Respiratorias

  Investigador Principal

  Raúl Méndez Ocaña

Abstract

Thymidine analogue resistance mutations (TAMs) selected under treatment with nucleoside analogues generate two distinct genotypic profiles in the HIV-1 reverse transcriptase (RT): (i) TAM1: M41L, L210W and T215Y, and (ii) TAM2: D67N, K70R and K219E/Q, and sometimes T215F. Secondary mutations, including thumb subdomain polymorphisms (e.g. R284K) have been identified in association with TAMs. We have identified mutational clusters associated with virological failure during salvage therapy with tenofovir/emtricitabine-based regimens. In this context, we have studied the role of R284K as a secondary mutation associated with mutations of the TAM1 complex.